CD4 and neoplasm: CD3+CD4+CD25+CD127low T cells made up 15.5% of CD4+-T cells in tumor samples compared to 7.8% and 5.0% of PBMCs of CRC patients or healthy controls respectively (p<0,005, Fig. 5C).